Scholarlink

<p>Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare subtype of salivary gland tumor that is generally considered a low-grade malignancy and is treated with surgical resection. Here, we report a case of P-EMC treated with definitive chemoradiotherapy. A 68-year-old man developed P-EMC with high-grade features, a Ki-67 labeling index of 60%, and rapidly progressing disease. The patient received concurrent chemoradiotherapy with carboplatin and paclitaxel, which resulted in a significant tumor size reduction. The patient is currently alive 9&#xa0;months after completing chemoradiotherapy without disease recurrence. This case suggests that platinum-based chemoradiotherapy is a viable therapeutic option for locally advanced, unresectable P-EMCs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Definitive chemoradiotherapy for pulmonary epithelial-myoepithelial carcinoma

  • 期刊论文

  • 发表日期：

    2025年6月8日

查看全文
  • Keijiro Yamauchi,
  • Masashi Yokoyama,
  • Kayo Ueda,
  • Riiko Komuta,
  • Hidetaka Tanabe,
  • So Takata,
  • Takafumi Yanase,
  • Yuki Hosono,
  • Shingo Satoh,
  • Naoko Morishita,
  • Hideo Mori,
  • Hidekazu Suzuki

摘要

Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare subtype of salivary gland tumor that is generally considered a low-grade malignancy and is treated with surgical resection. Here, we report a case of P-EMC treated with definitive chemoradiotherapy. A 68-year-old man developed P-EMC with high-grade features, a Ki-67 labeling index of 60%, and rapidly progressing disease. The patient received concurrent chemoradiotherapy with carboplatin and paclitaxel, which resulted in a significant tumor size reduction. The patient is currently alive 9 months after completing chemoradiotherapy without disease recurrence. This case suggests that platinum-based chemoradiotherapy is a viable therapeutic option for locally advanced, unresectable P-EMCs.